Glaukos Corporation Stock News

Stephens Inc. AR lifted its holdings in Glaukos Co. (NYSE:GKOS) by 80.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,922 shares of the medical instruments suppliers stock after purchasing an additional 2,638 shares during the period. Stephens Inc. ARs holdings in []

Glaukos Corporation (NYSE:GKOS) shares, rose in value on Friday, 12/17/21, with the stock price up by 4.41% to the previous days close as strong demand from buyers drove the stock to $43.78. Actively observing the price movement in the last trading, the stock closed the session at $41.93, falling within a range of $41.38 and Glaukos Corporation (NYSE: GKOS) Inclined 4.41%, Whats Next? Dont Be Too Excited Read More »

Related Stocks: ORSTED , DE , COUR , BBRI , CHR , BLI , GKOS ,

In the last trading session, 1.01 million shares of the Glaukos Corporation (NYSE:GKOS) were traded, and its beta was 1.68. Most recently the companys share price was $43.26, and it changed around $2.13 or 5.18% from the last close, which brings the market valuation of the company to $2.09B. GKOS currently trades at a discount Glaukos Corporation (NYSE: GKOS) Share Price Might Move Down By -36.39% Read More »

Taylor Frigon Capital Management LLC increased its position in shares of Glaukos Co. (NYSE:GKOS) by 57.9% during the third quarter, Holdings Channel.com reports. The institutional investor owned 108,478 shares of the medical instruments supplier’s stock after purchasing an additional 39,785 shares during the period. Glaukos accounts for 1.7% of Taylor Frigon Capital Management LLC’s investment […]

Glaukos Corporation (NYSE:GKOS) price on Friday, December 10, fall -3.10% below its previous days close as a downside momentum from buyers pushed the stocks value to $41.29. A look at the stocks price movement, the close in the last trading session was $42.61, moving within a range at $40.855 and $43.36. The beta value (5-Year Glaukos Corporation (GKOS) With A Potential Upside Of More Than -64.69% Read More »

Related Stocks: ZBH , PINS , HEI.A , LEVI , PNFP , G , ONON , DLTR , ZEN , TT , GKOS ,

Analysts expect that Glaukos Co. (NYSE:GKOS) will post sales of $67.60 million for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Glaukos earnings, with estimates ranging from $67.20 million to $68.40 million. Glaukos reported sales of $73.23 million during the same quarter last year, which would indicate a negative year []

Wall Street brokerages predict that Glaukos Co. (NYSE:GKOS) will announce earnings per share of ($0.35) for the current fiscal quarter, according to Zacks Investment Research. Six analysts have provided estimates for Glaukos earnings, with the highest EPS estimate coming in at ($0.32) and the lowest estimate coming in at ($0.37). Glaukos reported earnings per share []

ICU Medical (NASDAQ:ICUI) and Glaukos (NYSE:GKOS) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations. Valuation and Earnings This table compares ICU Medical and Glaukos top-line revenue, earnings per share (EPS) []

Wells Fargo & Company MN grew its position in shares of Glaukos Co. (NYSE:GKOS) by 12.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 83,880 shares of the medical instruments suppliers stock after purchasing an additional 9,443 shares during the period. Wells Fargo []

Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and solid performing iStent technology.

GKOS earnings call for the period ending November 29, 2021.